A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Blood-based biomarkers represent a less invasive and potentially cheaper approach for aiding Alzheimer’s disease (AD) detection compared with cerebrospinal fluid and some neuroimaging biomarkers. Acknowledging that many in the field have made great progress, here we review some of the work that our group has pursued to identify and validate blood-based proteomic biomarkers through both case control and AD pathology endophenotype-based approaches. Our focus is primarily to identify a minimally invasive and hopefully cost-effective blood-based biomarker to reduce screen failure in clinical trials where participants have prodromal or even pre-clinical disease. We summarize some of the key findings and approaches taken in these biomarker studies, while addressing the main challenges, including that of limited replication in the field, and discuss opportunities for biomarker development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“A plaque burden, increased levels of tau in CSF, and brain atrophy are detected 15 years before expected symptom onset while global cognitive impairment is detected 5 years before symptom onset [39, 40], suggesting that such a study design could be effective in detecting blood-based biomarkers for preclinical disease.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“…levels of tau in CSF, and brain atrophy are detected 15 years before expected symptom onset while global cognitive impairment is detected 5 years before symptom onset [39, 40], suggesting that such a study design could be effective in detecting blood-based biomarkers for preclinical disease.”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“published soon after [16], persuaded us that there is a signal in blood; but the question remains, can that signal be translated to a replicable and useful biomarker?”
BackgroundBonini, P., Plebani, M., Ceriotti, F., & Rubboli, F. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.5.691 · Cited by 850
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
Self-citationThambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationSnowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309 · cited 1×
“A series of studies, including some from our own laboratories [67, 73–78], are beginning to nominate metabolite or lipidomic markers from blood and then there are other genomics including microRNAs and epigenetic changes, transcriptomics, and other markers.”
ResultSelf-citationAlzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 5×
“As an alternative high dimensionality detection technology not biased toward abundant proteins, we turned to the aptamer capture, SOMAscan array, developed by SomaLogic to test 1001 proteins in blood samples from 691 subjects [33].”
BackgroundMethodInfluentialSelf-citationPlasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · cited 1×
“reported that the gene encoding clusterin was the strongest association with AD after APOE, and the association between clusterin protein levels in blood and some aspect of disease was repeated by later studies from our own group [33, 43–45] as well as those from others [46, 47].”
ResultGezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130497 · Cited by 188
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Self-citationDeveloping novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
Self-citationInflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064971 · Cited by 160 · cited 3×
“, [54] AddNeuroMed cohort: 117 AD, 122 MCI and 112 CTL IL-4, IL-10, G-CSF, IL-2, IFN- , and PDGF Luminex -six proteins were associated with fast cognitive decline Kiddle et al.”
BackgroundInfluentialSelf-citationEvaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100 · cited 4×
“, [59] ADNI cohort: 16 AD, 52 MCI and 3 controls 146 proteins probed Human Discovery Multi-Analyte Profile (MAP) and Luminex -Leptin was significantly associated with CSF A 1-42 Westwood et al.”
BackgroundMethodInfluentialSelf-citationPrognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression
Yang, H., Lyutvinskiy, Y., Herukka, S.-K., Soininen, H., Rutishauser, D., & Zubarev, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132102 · Cited by 52
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34 · cited 1×
“While this study refutes the superficial ‘nothing replicates’ dismissal, it remains the case that in the field as a whole, most nominated biomarkers fail replication posing a substantial challenge to development [60].”
ResultProgress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Killick, R., Hughes, T. R., Morgan, B. P., & Lovestone, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.008 · Cited by 17 · cited 1×
“These findings in mice suggest a role in the disease process and while the mechanism underlying such a role is not known, we find that in neurons from mice lacking their equivalent of the AD susceptibility gene CR1, the levels of CFH and phosphorylated tau are significantly, and substantially, decreased [24].”
BackgroundSelf-citation
Research works printed but not linked: 57
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1111/j.1526-4610.2011.01959.x · DOI · Paper page
- 10.1016/j.pneurobio.2012.06.007 · DOI
- 10.1111/j.1755-5949.2009.00104.x · DOI · Paper page
- 10.1002/acn3.313 · DOI
- 10.2174/1567205013666151116130301 · DOI
- 10.3389/fneur.2015.00236 · DOI · Paper page
- 10.1016/j.jalz.2013.01.013 · DOI · Paper page
- 10.1093/brain/awl279 · DOI · Paper page
- 10.1097/WNR.0000000000000661 · DOI
- 10.3233/JAD-142742 · DOI
- 10.1080/13547500802445199 · DOI · Paper page
- 10.1038/mp.2016.206 · DOI · Paper page
- 10.3233/JAD-2012-112012 · DOI · Paper page
- 10.1007/s00415-008-0006-8 · DOI
- Fyfe I, 2017, Nat Rev Neurol, 13, 5
- 10.3233/JAD-2010-100279 · DOI · Paper page
- 10.1186/1477-5956-12-5 · DOI
- 10.1016/j.neulet.2015.04.014 · DOI
- 10.1001/archneurol.2012.1282 · DOI · Paper page
- 10.1001/archneurol.2010.215 · DOI · Paper page
- 10.3233/JAD-160420 · DOI · Paper page
- 10.1186/1479-5876-10-217 · DOI · Paper page
- 10.1002/gps.1810 · DOI · Paper page
- 10.1021/acs.jproteome.5b00892 · DOI
- 10.1016/j.neuroimage.2011.07.056 · DOI · Paper page
- 10.1016/j.jalz.2014.05.1749 · DOI · Paper page
- 10.3233/JAD-130380 · DOI · Paper page
- 10.3233/JAD-150036 · DOI · Paper page
- 10.1371/journal.pone.0028527 · DOI · Paper page
- 10.3233/JAD-2011-110611 · DOI
- 10.1111/j.1749-6632.2009.05066.x · DOI · Paper page
- 10.1016/j.neurobiolaging.2009.03.011 · DOI · Paper page
- 10.1038/nm1653 · DOI · Paper page
- 10.3233/JAD-140669 · DOI · Paper page
- 10.3233/JAD-2010-101350 · DOI · Paper page
- 10.1016/j.dadm.2014.11.005 · DOI · Paper page
- 10.3233/JAD-151155 · DOI
- 10.1093/clinchem/43.8.1348 · DOI · Paper page
- 10.1016/j.jalz.2014.08.099 · DOI · Paper page
- 10.4236/aad.2012.13007 · DOI
- 10.3233/CBM-2009-0137 · doi:10.3233/cbm-2009-0137
- 10.1038/nm.3466 · DOI · Paper page
- 10.1016/j.jalz.2015.12.008 · DOI · Paper page
- 10.1016/j.jalz.2017.01.020 · DOI · Paper page
- 10.1016/j.dadm.2016.09.003 · DOI · Paper page
- 10.1016/j.jalz.2017.01.003 · DOI
- 10.3233/JAD-150020 · DOI · Paper page
- 10.1038/mp.2013.40 · DOI
- 10.1038/tp.2015.205 · DOI
- 10.3233/JAD-160645 · DOI · Paper page
- 10.1016/j.neurobiolaging.2013.08.001 · DOI · Paper page
- 10.1016/j.jalz.2016.08.003 · DOI · Paper page
- 10.1038/tp.2014.127 · DOI · Paper page
- 10.1186/s13195-017-0258-6 · DOI
Cited by
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“Recently there has been a surge in finding blood biomarkers appropriate for repeated evaluations throughout the disease progression over a time-frame for an interventional/treatment study [57].”
BackgroundLarge-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00064-0 · Cited by 212
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Rahman, M. R., Islam, T., Zaman, T., Shahjaman, M., Karim, M. R., Huq, F., Quinn, J. M. W., Holsinger, R. M. D., Gov, E., & Moni, M. A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.07.018 · Cited by 136
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Metadata
- Authors
- Shi, L., Baird, A. L., Westwood, S., Hye, A., Dobson, R., Thambisetty, M., & Lovestone, S.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-12-01
- Volume
- 62
- Issue
- 3
- Pages
- 1181-1198
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2772836221
- Cited by
- 90
- References
- 22
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.